vs
Side-by-side financial comparison of Gilead Sciences (GILD) and Block, Inc. (XYZ). Click either name above to swap in a different company.
Gilead Sciences is the larger business by last-quarter revenue ($7.9B vs $6.3B, roughly 1.3× Block, Inc.). Gilead Sciences runs the higher net margin — 27.5% vs 1.9%, a 25.7% gap on every dollar of revenue. On growth, Gilead Sciences posted the faster year-over-year revenue change (4.7% vs 3.6%). Gilead Sciences produced more free cash flow last quarter ($3.1B vs $579.8M). Over the past eight quarters, Gilead Sciences's revenue compounded faster (8.9% CAGR vs 2.4%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Block, Inc. is an American technology company and a financial services provider for consumers and merchants. Founded in 2009 by Jack Dorsey, it is the U.S. market leader in point-of-sale systems. As of 2024, Block serves 57 million users and 4 million sellers, processing $241 billion in payments annually.
GILD vs XYZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $6.3B |
| Net Profit | $2.2B | $115.8M |
| Gross Margin | 79.5% | 45.9% |
| Operating Margin | 25.0% | 7.8% |
| Net Margin | 27.5% | 1.9% |
| Revenue YoY | 4.7% | 3.6% |
| Net Profit YoY | 22.4% | -94.1% |
| EPS (diluted) | $1.75 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.9B | $6.3B | ||
| Q3 25 | $7.8B | $6.1B | ||
| Q2 25 | $7.1B | $6.1B | ||
| Q1 25 | $6.7B | $5.8B | ||
| Q4 24 | $7.6B | $6.0B | ||
| Q3 24 | $7.5B | $6.0B | ||
| Q2 24 | $7.0B | $6.2B | ||
| Q1 24 | $6.7B | $6.0B |
| Q4 25 | $2.2B | $115.8M | ||
| Q3 25 | $3.1B | $461.5M | ||
| Q2 25 | $2.0B | $538.5M | ||
| Q1 25 | $1.3B | $189.9M | ||
| Q4 24 | $1.8B | $1.9B | ||
| Q3 24 | $1.3B | $283.8M | ||
| Q2 24 | $1.6B | $195.3M | ||
| Q1 24 | $-4.2B | $472.0M |
| Q4 25 | 79.5% | 45.9% | ||
| Q3 25 | 79.8% | 43.5% | ||
| Q2 25 | 78.8% | 41.9% | ||
| Q1 25 | 76.9% | 39.7% | ||
| Q4 24 | 79.1% | 38.3% | ||
| Q3 24 | 79.1% | 37.6% | ||
| Q2 24 | 77.8% | 36.3% | ||
| Q1 24 | 76.8% | 35.2% |
| Q4 25 | 25.0% | 7.8% | ||
| Q3 25 | 42.8% | 6.7% | ||
| Q2 25 | 34.9% | 8.0% | ||
| Q1 25 | 33.6% | 5.7% | ||
| Q4 24 | 32.4% | 0.2% | ||
| Q3 24 | 11.8% | 5.4% | ||
| Q2 24 | 38.0% | 5.0% | ||
| Q1 24 | -64.6% | 4.2% |
| Q4 25 | 27.5% | 1.9% | ||
| Q3 25 | 39.3% | 7.5% | ||
| Q2 25 | 27.7% | 8.9% | ||
| Q1 25 | 19.7% | 3.3% | ||
| Q4 24 | 23.6% | 32.3% | ||
| Q3 24 | 16.6% | 4.7% | ||
| Q2 24 | 23.2% | 3.2% | ||
| Q1 24 | -62.4% | 7.9% |
| Q4 25 | $1.75 | $0.19 | ||
| Q3 25 | $2.43 | $0.74 | ||
| Q2 25 | $1.56 | $0.87 | ||
| Q1 25 | $1.04 | $0.30 | ||
| Q4 24 | $1.43 | $3.06 | ||
| Q3 24 | $1.00 | $0.45 | ||
| Q2 24 | $1.29 | $0.31 | ||
| Q1 24 | $-3.34 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | $6.6B |
| Total DebtLower is stronger | $24.9B | — |
| Stockholders' EquityBook value | $22.7B | $22.2B |
| Total Assets | $59.0B | $39.5B |
| Debt / EquityLower = less leverage | 1.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.0M | $6.6B | ||
| Q3 25 | $19.0M | $8.3B | ||
| Q2 25 | $69.0M | $6.4B | ||
| Q1 25 | — | $7.1B | ||
| Q4 24 | — | $8.1B | ||
| Q3 24 | — | $8.3B | ||
| Q2 24 | — | $7.8B | ||
| Q1 24 | — | $5.8B |
| Q4 25 | $24.9B | — | ||
| Q3 25 | $24.9B | $7.3B | ||
| Q2 25 | $24.9B | $5.1B | ||
| Q1 25 | $25.0B | $5.1B | ||
| Q4 24 | $26.7B | $6.1B | ||
| Q3 24 | $23.2B | $6.1B | ||
| Q2 24 | $23.3B | $6.1B | ||
| Q1 24 | $25.2B | $4.1B |
| Q4 25 | $22.7B | $22.2B | ||
| Q3 25 | $21.5B | $22.5B | ||
| Q2 25 | $19.7B | $22.2B | ||
| Q1 25 | $19.2B | $21.5B | ||
| Q4 24 | $19.3B | $21.3B | ||
| Q3 24 | $18.5B | $19.9B | ||
| Q2 24 | $18.3B | $19.3B | ||
| Q1 24 | $17.5B | $19.0B |
| Q4 25 | $59.0B | $39.5B | ||
| Q3 25 | $58.5B | $39.2B | ||
| Q2 25 | $55.7B | $36.9B | ||
| Q1 25 | $56.4B | $36.4B | ||
| Q4 24 | $59.0B | $36.8B | ||
| Q3 24 | $54.5B | $36.4B | ||
| Q2 24 | $53.6B | $37.5B | ||
| Q1 24 | $56.3B | $35.6B |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.16× | 0.32× | ||
| Q2 25 | 1.27× | 0.23× | ||
| Q1 25 | 1.30× | 0.24× | ||
| Q4 24 | 1.38× | 0.29× | ||
| Q3 24 | 1.26× | 0.31× | ||
| Q2 24 | 1.28× | 0.32× | ||
| Q1 24 | 1.44× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $621.0M |
| Free Cash FlowOCF − Capex | $3.1B | $579.8M |
| FCF MarginFCF / Revenue | 39.4% | 9.3% |
| Capex IntensityCapex / Revenue | 2.6% | 0.7% |
| Cash ConversionOCF / Net Profit | 1.52× | 5.36× |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | $2.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3B | $621.0M | ||
| Q3 25 | $4.1B | $1.5B | ||
| Q2 25 | $827.0M | $374.3M | ||
| Q1 25 | $1.8B | $133.3M | ||
| Q4 24 | $3.0B | $13.8M | ||
| Q3 24 | $4.3B | $684.8M | ||
| Q2 24 | $1.3B | $519.4M | ||
| Q1 24 | $2.2B | $489.4M |
| Q4 25 | $3.1B | $579.8M | ||
| Q3 25 | $4.0B | $1.4B | ||
| Q2 25 | $720.0M | $343.0M | ||
| Q1 25 | $1.7B | $101.5M | ||
| Q4 24 | $2.8B | $-13.2M | ||
| Q3 24 | $4.2B | $628.2M | ||
| Q2 24 | $1.2B | $481.0M | ||
| Q1 24 | $2.1B | $457.4M |
| Q4 25 | 39.4% | 9.3% | ||
| Q3 25 | 51.0% | 22.9% | ||
| Q2 25 | 10.2% | 5.7% | ||
| Q1 25 | 24.8% | 1.8% | ||
| Q4 24 | 37.4% | -0.2% | ||
| Q3 24 | 55.2% | 10.5% | ||
| Q2 24 | 17.2% | 7.8% | ||
| Q1 24 | 31.6% | 7.7% |
| Q4 25 | 2.6% | 0.7% | ||
| Q3 25 | 1.9% | 0.8% | ||
| Q2 25 | 1.5% | 0.5% | ||
| Q1 25 | 1.6% | 0.6% | ||
| Q4 24 | 1.9% | 0.4% | ||
| Q3 24 | 1.9% | 0.9% | ||
| Q2 24 | 1.9% | 0.6% | ||
| Q1 24 | 1.6% | 0.5% |
| Q4 25 | 1.52× | 5.36× | ||
| Q3 25 | 1.35× | 3.14× | ||
| Q2 25 | 0.42× | 0.70× | ||
| Q1 25 | 1.34× | 0.70× | ||
| Q4 24 | 1.67× | 0.01× | ||
| Q3 24 | 3.44× | 2.41× | ||
| Q2 24 | 0.82× | 2.66× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
XYZ
| US | $5.7B | 91% |
| Non Us | $560.9M | 9% |
